Active substance
Diclofenac
- SFDA 131
- US FDA 90
- Health Canada 23
- US price lines 22
- NHS prices 19
- Safety 16
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| ANNUVA 50 mg Tablet | 50 mg | Tablet · Oral use | 20 Blister | SAR 17.65 | Generic · Prescription | DAMMAM PHARMA | Valid |
| APO-DICLO 50 mg enteric-coated tablet | 50 mg | Enteric-coated tablet · Oral use | 20 Blister | SAR 19.80 | Generic · Prescription | APOTEX | Valid |
| AQUAFLAM 50 MG SACHET | 50 mg | Powder for oral solution · Oral use | 12 Sachet | SAR 24.00 | Generic · Prescription | RIYADH PHARMA | Valid |
| Avotrene Emulgel | 1 % | Gel · Topical | 1 Tube | SAR 14.40 | Generic · OTC | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
| CATAFAST 50 MG SACHET | 50 mg | Powder for oral suspension · Oral use | 9 Sachet | SAR 18.00 | NCE · Prescription | NOVARTIS PHARMA AG | Valid |
| CATAFLAM 50MG TABLET | 50 mg | Coated tablet · Oral use | 20 Blister | SAR 31.70 | Generic · Prescription | NOVARTIS PHARMA AG | Valid |
| CLOFAST 1% GEL | 1 % | Gel · Topical | 1 Tube | SAR 3.50 | Generic · OTC | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CLOFAST-P 50 mg tablet | 50 mg | Tablet · Oral use | 20 Blister | SAR 9.10 | Generic · Prescription | OMAN PHARMACEUTICAL PRODUCTS | Valid |
| CLOFEN 75MG INJECTION | 25 mg/ml | Solution for injection · Parenteral use | 5 Ampoule | SAR 25.65 | Generic · Prescription | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CLOFEN CREAMAGEL 1% | 1 % | Cream · Topical | 1 Tube | SAR 3.90 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| CLOFEN CREAMAGEL 1% | 1 % | Cream · Topical | 1 Tube | SAR 8.00 | Generic · OTC | Gulf Pharmaceutical Industries (Julphar) | Valid |
| Catafenac | 50 mg | Powder for oral solution · Oral use | 20 Sachet | SAR 40.00 | Generic · Prescription | Saudi Amarox | Valid |
| Catafenac | 50 mg | Powder for oral solution · Oral use | 10 Sachet | SAR 20.00 | Generic · Prescription | Saudi Amarox | Valid |
| DICLAC 75MG ID TABLETS | 75 mg | Prolonged-release tablet · Oral use | 20 Blister | SAR 24.85 | Generic · Prescription | HEXAL | Valid |
| DICLOGESIC | 12.5 mg | Suppository · Rectal use | 10 Blister | SAR 4.60 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOGESIC | 100 mg | Suppository · Rectal use | 5 Blister | SAR 11.40 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOGESIC 50MG SUPPOSITORY | 50 mg | Suppository · Rectal use | 10 Blister | SAR 6.35 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOGESIC RETARD | 100 mg | Film-coated tablet · Oral use | 10 Blister | SAR 9.05 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOGESIC RETARD | 100 mg | Capsule · Oral use | 12 Blister | SAR 17.20 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOGESIC RETARD | 100 mg | Coated tablet · Oral use | 500 Blister | SAR 345.20 | Generic · Prescription | DAR ALDAWA | Valid |
| DICLOMAX | 50 mg | Tablet · Oral use | 160 Blister | SAR 141.20 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| DICLOMAX 1% EMULGEL | 1 % | Gel · Topical | 1 Tube | SAR 10.55 | Generic · OTC | Jazeera Pharmaceutical Industries (JPI) | Valid |
| DICLOMAX 25MG TAB | 25 mg | Tablet · Oral use | 30 Blister | SAR 14.85 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| DICLOMAX 50 MG TAB | 50 mg | Tablet · Oral use | 20 Blister | SAR 19.80 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| DICLON 1% EMULGEL | 1 % | Gel · Topical | 1 Tube | SAR 9.30 | Generic · OTC | MEDPHARMA PHARMACEUTICAL & CHEMICAL INDUSTRIES | Valid |
106 more — full table
Indications — CHI Daman Drug Formulary
ACUTE PANCREATITIS-PAIN MANAGEMENT; ANKYLOSING SPONDYLITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; CHRONIC PANCREATITIS; DENTAL ABSCESS-DENTAL PAIN; ENDOMETRIOSIS; ENTEROPATHIC ARTHROPATHIES, UNSPECIFIED SITE REACTIVE ARTHROPATHY, UNSPECIFIED; EPIDERMOLYSIS BULLOSA; GOUT; INFLUENZA-SYMPTOMATIC TREATMENT; JUVENILE IDIOPATHIC ARTHRITIS (JIA); LOW BACK PAIN; MENSTRUAL DISORDERS; MIGRAINE/ HEADACHE; MUCOSAL ULCERATION-SUPPORTIVE AGENTS; NECROTIZING PERIODONTITIS AND NECROTIZING ULCERATIVE GINGIVITIS; NON-INFECTIOUS UVEITIS; OSTEOARTHRITIS; PAIN MANAGEMENT IN CANCER PATIENTS; PERICORONITIS; POSTOPERATIVE PAIN; PSORIATIC ARTHRITIS; RENAL AND URETERIC STONES; RHEUMATOID ARITHRITIS; SICKLE CELL DISEASE - PAIN MANAGEMENT
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| DICLOFENAC SODIUM | 50MG; 75MG | tablet, delayed release · oral | ACTAVIS ELIZABETH | Prescription | 26 Mar 1996 |
| DICLOFENAC POTASSIUM | 50MG | tablet · oral | TEVA | Prescription | 6 Aug 1998 |
| DICLOFENAC SODIUM | 75MG; 25MG; 50MG | tablet, delayed release · oral | CARLSBAD | Prescription | 13 Nov 1998 |
| DICLOFENAC POTASSIUM | 50MG; 25MG; 75MG | tablet · oral | RUBICON RESEARCH | Prescription | 20 Nov 1998 |
| DICLOFENAC POTASSIUM | 50MG | tablet · oral | RISING | Prescription | 26 Jul 1999 |
| DICLOFENAC SODIUM | 100MG | tablet, extended release · oral | VPNA | Prescription | 11 Feb 2000 |
| DICLOFENAC SODIUM | 100MG | tablet, extended release · oral | AUROBINDO PHARMA USA | Prescription | 13 Dec 2001 |
| DICLOFENAC SODIUM | 50MG; 75MG | tablet, delayed release · oral | AUROBINDO PHARMA USA | Prescription | 12 Feb 2002 |
| DICLOFENAC SODIUM | 100MG | tablet, extended release · oral | DEXCEL LTD | Prescription | 6 Nov 2002 |
| CATAFLAM | 50MG; 25MG | tablet · oral | AMICI PHARMA | Prescription | 18 Mar 2004 |
| DICLOFENAC SODIUM | 75MG | tablet, delayed release · oral | UNIQUE | Prescription | 8 Jun 2007 |
| VOLTAREN ARTHRITIS PAIN | 1% | gel · topical | HALEON US HOLDINGS | Over-the-counter | 17 Oct 2007 |
| DICLOFENAC SODIUM | 0.1% | solution/drops · ophthalmic | RISING | Prescription | 28 Dec 2007 |
| DICLOFENAC SODIUM | 0.1% | solution/drops · ophthalmic | BAUSCH AND LOMB | Prescription | 28 Dec 2007 |
| DICLOFENAC SODIUM | 0.1% | solution/drops · ophthalmic | SANDOZ | Prescription | 6 Feb 2008 |
| DICLOFENAC SODIUM | 0.1% | solution/drops · ophthalmic | RUBICON RESEARCH | Prescription | 13 Nov 2008 |
| ZIPSOR | 25MG | capsule · oral | COSETTE | Prescription | 16 Jun 2009 |
| CAMBIA | 50MG | for solution · oral | COSETTE | Prescription | 17 Jun 2009 |
| DICLOFENAC SODIUM | 25MG; 50MG | tablet, delayed release · oral | UNIQUE | Prescription | 1 Dec 2010 |
| DICLOFENAC SODIUM | 1.5% | solution · topical | WATSON LABS INC | Prescription | 24 Nov 2014 |
| DICLOFENAC SODIUM | 1.5% | solution · topical | SUN PHARMA CANADA | Prescription | 26 Nov 2014 |
| DICLOFENAC SODIUM | 1.5% | solution · topical | LUPIN | Prescription | 20 Aug 2015 |
| DICLOFENAC SODIUM | 0.1% | solution/drops · ophthalmic | ALTAIRE PHARMS INC | Prescription | 16 Nov 2015 |
| DICLOFENAC SODIUM | 3% | gel · topical | ACTAVIS MID ATLANTIC | Prescription | 2 Dec 2015 |
| DICLOFENAC SODIUM | 1.5% | solution · topical | NOVEL LABS INC | Prescription | 9 Dec 2015 |
65 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-DICLO | 00839175 | 25 MG | TABLET (ENTERIC-COATED) · ORAL | APOTEX INC |
| APO-DICLO | 00839183 | 50 MG | TABLET (ENTERIC-COATED) · ORAL | APOTEX INC |
| APO-DICLO SR | 02091194 | 100 MG / SRT | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| APO-DICLO SR | 02162814 | 75 MG | TABLET (EXTENDED-RELEASE) · ORAL | APOTEX INC |
| CAMBIA | 02381680 | 50 MG / SACHET | POWDER FOR SOLUTION · ORAL | ARALEZ PHARMACEUTICALS CANADA INC |
| DICLOFENAC | 02475065 | 0.1 % / W/V | SOLUTION · OPHTHALMIC | PHARMA STULLN INC. |
| JAMP DICLOFENAC | 02534525 | 0.1 % / W/V | SOLUTION · OPHTHALMIC | JAMP PHARMA CORPORATION |
| JAMP DICLOFENAC FOR SOLUTION | 02563290 | 50 MG / SACHET | POWDER FOR SOLUTION · ORAL | JAMP PHARMA CORPORATION |
| JAMP DICLOFENAC TOPICAL SOLUTION | 02472309 | 1.5 % / W/W | SOLUTION · TOPICAL | JAMP PHARMA CORPORATION |
| PENNSAID | 02247265 | 1.5 % / W/W | SOLUTION · TOPICAL | KNIGHT THERAPEUTICS INC. |
| PMS-DICLOFENAC | 02302616 | 25 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PMS-DICLOFENAC | 02302624 | 50 MG | TABLET (DELAYED-RELEASE) · ORAL | PHARMASCIENCE INC |
| PRO-DICLOFENAC | 00870978 | 50 MG | TABLET (DELAYED-RELEASE) · ORAL | PRO DOC LIMITEE |
| RIVA-DICLOFENAC | 02560631 | 50 MG / SACHET | POWDER FOR SOLUTION · ORAL | LABORATOIRE RIVA INC. |
| SANDOZ DICLOFENAC RAPIDE | 02261774 | 50 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| SANDOZ-DICLOFENAC | 02261928 | 50 MG | SUPPOSITORY · RECTAL | SANDOZ CANADA INCORPORATED |
| TARO-DICLOFENAC | 02420988 | 1.5 % / W/W | SOLUTION · TOPICAL | TARO PHARMACEUTICALS INC |
| TARO-DICLOFENAC POTASSIUM POWDER FOR ORAL SOLUTION | 02564475 | 50 MG / SACHET | POWDER FOR SOLUTION · ORAL | TARO PHARMACEUTICALS INC |
| TEVA-DICLOFENAC EC | 00808547 | 50 MG | TABLET (ENTERIC-COATED) · ORAL | TEVA CANADA LIMITED |
| TEVA-DICLOFENAC SR | 02158582 | 75 MG | TABLET (EXTENDED-RELEASE) · ORAL | TEVA CANADA LIMITED |
| TEVA-DICLOFENAC-K | 02239355 | 50 MG | TABLET · ORAL | TEVA CANADA LIMITED |
| VOLTAREN | 00632724 | 50 MG | SUPPOSITORY · RECTAL | NOVARTIS PHARMACEUTICALS CANADA INC |
| VOLTAREN RAPIDE | 00881635 | 50 MG | TABLET · ORAL | NOVARTIS PHARMACEUTICALS CANADA INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | DICLOFENAC 0.1% EYE DROPS | $1.69541 | per ML | 23 Sep 2026 |
| US NADAC | DICLOFENAC 0.1% EYE DROPS | $1.7496 | per ML | 23 Sep 2026 |
| US NADAC | DICLOFENAC 1.5% TOPICAL SOLN | $0.12941 | per ML | 23 Sep 2026 |
| US NADAC | DICLOFENAC 2% SOLUTION PUMP | $0.42962 | per GM | 23 Sep 2026 |
| US NADAC | DICLOFENAC POT 25 MG TABLET | $4.56677 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC POT 50 MG POWDR PKT | $10.97187 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC POT 50 MG TABLET | $0.11246 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC POTASSIUM 25 MG CAP | $2.80711 | per EA | 30 Sep 2026 |
| US NADAC | DICLOFENAC SOD DR 25 MG TAB | $0.68438 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC SOD DR 50 MG TAB | $0.06233 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC SOD DR 75 MG TAB | $0.06194 | per EA | 23 Sep 2026 |
| US NADAC | DICLOFENAC SOD EC 25 MG TAB | $0.68438 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Diclofenac 0.1% eye drops | £6.68 | 5 ml | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 0.1% eye drops 0.3ml unit dose preservative free | £32.00 | 40 unit dose | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 100mg suppositories | £2.73 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 12.5mg suppositories | £0.70 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 140mg medicated plasters | £13.01 | 5 plaster | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 25mg suppositories | £1.24 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 50mg suppositories | £2.04 | 10 suppository | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac 75mg/3ml solution for injection ampoules | £9.91 | 10 ampoule | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac potassium 50mg tablets | £7.94 | 30 tablet | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac sodium 1% gel | £6.45 | 100 gram | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac sodium 100mg modified-release capsules | £8.20 | 28 capsule | 1 Oct 2026 |
| NHS Drug Tariff | Diclofenac sodium 100mg modified-release tablets | £11.33 | 28 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 21 Nov 2024 ARTHROTEC — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 CAMBIA — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 PENNSAID — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 SOLARAZE — safety-related labeling change
Labeling sections changed: Boxed Warning; Contraindications; Warnings and Precautions; Adverse Reactions; Drug Interactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 ZIPSOR — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 21 Nov 2024 ZORVOLEX — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 3 Nov 2021 VOLTAREN ARTHRITIS PAIN — safety-related labeling change
Labeling sections changed: Warnings and Precautions - US FDA 28 Apr 2021 CATAFLAM — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 VOLTAREN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 28 Apr 2021 VOLTAREN-XR — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 May 2016 DYLOJECT — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 May 2016 PENNSAID — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 May 2016 VOLTAREN — safety-related labeling change
Labeling sections changed: Boxed Warning; Warnings and Precautions; Patient Counseling Information / Patient Information / Medication Guide - MHRA 11 Dec 2014 Diclofenac: public consultation on availability as a pharmacy medicine
Public consultation launched on the continued availability of oral diclofenac as a pharmacy (P) medicine and on risk-minimisation measures advised by the Commission on Human Medicines. - MHRA 11 Dec 2014 Diclofenac: new contraindications and warnings
New recommendations after a Europe-wide review of cardiovascular safety.
Combinations containing Diclofenac
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.